Plancorp LLC’s Recursion Pharmaceuticals RXRX Stock Holding History

Plancorp LLC’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$229K	Sell	69,500 -15,000	-18%	-$49.9K	0.01%	383
2026 Q1	$277K	Hold	84,500	–	–	0.01%	306
2025 Q4	$346K	Sell	84,500 -5,000	-6%	-$24.8K	0.01%	259
2025 Q3	$437K	Hold	89,500	–	–	0.01%	242
2025 Q2	$453K	Sell	89,500 -176	-0.2%	-$865	0.02%	238
2025 Q1	$474K	Buy	89,676 +2,092	+2%	+$15.3K	0.02%	215
2024 Q4	$592K	Buy	87,584 +10,000	+13%	+$67.2K	0.02%	171
2024 Q3	$511K	Buy	77,584 +6,974	+10%	+$50K	0.02%	191
2024 Q2	$530K	Buy	70,610 +43,000	+156%	+$375K	0.02%	174
2024 Q1	$275K	Buy	27,610 +17,000	+160%	+$189K	0.01%	244
2023 Q4	$105K	Sell	10,610 -90	-0.8%	-$642	0.01%	275
2023 Q3	$81.9K	Buy	+10,700	New	+$107K	﹤0.01%	256

Other funds holding RXRX

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

1WA

180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

SFS

Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return

Kieckhefer Group Mequon, Wisconsin $246M AUM 51.29% 1-Year Est. Return

TMC

Themes Management Co Greenwich, Connecticut $151M AUM

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

AWM

Accel Wealth Management Waverly, Iowa $444M AUM 31.14% 1-Year Est. Return

NWMG

National Wealth Management Group Cincinnati, Ohio $323M AUM 39.23% 1-Year Est. Return

Plancorp LLC's RXRX Position: Q2 2026 in Review

Plancorp LLC reduced its Recursion Pharmaceuticals (RXRX) stake by 18% in Q2 2026, selling an estimated $49.9K and leaving 69,500 shares worth $229K. The position accounts for 0.01% of the portfolio, ranked #383.

Plancorp LLC first reported a position in RXRX in Q3 2023 and has held it in 12 quarters since. The position peaked at $592K in Q4 2024. 50 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Plancorp LLC held 69,500 shares of Recursion Pharmaceuticals worth $229K as of Q2 2026.
Plancorp LLC sold 15,000 Recursion Pharmaceuticals shares in Q2 2026, an estimated $49.9K.
Recursion Pharmaceuticals made up 0.01% of Plancorp LLC's portfolio in Q2 2026, its #383 holding.
Plancorp LLC first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
Plancorp LLC's Recursion Pharmaceuticals position peaked at $592K in Q4 2024.
50 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Plancorp LLC's 13F filing for Q2 2026, filed 14 Jul 2026.